World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
100321
World Ranking
7463
National Ranking
231

Overview

Céleste Lebbé is affiliated with the Hôpitaux Universitaires Paris-Ouest in France. Their research primarily focuses on oncology within the field of medicine, with significant work in oncology, molecular biology, immunology, epidemiology, and dermatology. Lebbé has contributed extensively to topics including cancer immunotherapy and biomarkers, CAR-T cell therapy research, melanoma and MAPK pathways, cutaneous melanoma detection and management, immunotherapy and immune responses, polyomavirus and related diseases, and nonmelanoma skin cancer studies.

Lebbé's publishing record includes numerous articles in several key venues. Frequent publication venues feature:

  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Annals of Oncology
  • Annales de Dermatologie et de Vénéréologie - FMC
  • Annales de Dermatologie et de Vénéréologie

Their recent papers include:

  • "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma" (2022, Zurich Open Repository and Archive, University of Zurich)
  • "Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial" (2021, The Lancet Oncology)
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment" (2020, European Journal of Cancer)
  • "Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma" (2024, New England Journal of Medicine)
  • "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022" (2022, European Journal of Cancer)

Lebbé collaborates frequently with several researchers, including:

  • Laurent Mortier
  • Barouyr Baroudjian
  • Paolo A. Ascierto
  • Caroline Robert
  • Philippe Saïag

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Nivolumab in previously untreated melanoma without BRAF mutation.

    Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

    Jedd D Wolchok;Bart Neyns;Gerald Linette;Sylvie Negrier

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Howard L. Kaufman;Jeffery Russell;Omid Hamid;Shailender Bhatia

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Jason Chesney;Igor Puzanov;Frances Collichio;Parminder Singh

  • Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

    Michael A. Davies;Philippe Saiag;Caroline Robert;Jean Jacques Grob

  • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

    G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas

  • Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Sandra P D'Angelo;James Larkin;Jeffrey A Sosman;Celeste Lebbé

Frequent Co-Authors

Caroline Robert
Caroline Robert University of Paris-Saclay
Martine Bagot
Martine Bagot Université Paris Cité
Georgina V. Long
Georgina V. Long University of Sydney
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Anne Janin
Anne Janin Université Paris Cité
Reinhard Dummer
Reinhard Dummer University of Zurich
Claus Garbe
Claus Garbe University of Tübingen
Axel Hauschild
Axel Hauschild Kiel University
Raphaël Porcher
Raphaël Porcher Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring career options in medicine goes beyond the traditional MD route. Many students find rewarding healthcare roles through alternative degree pathways and online programs. For registered nurses, pursuing a bachelor's degree can open doors to advanced positions and higher pay. There are cheap rn to bsn programs available online, making it easier to advance your education without significant financial strain.

If you have a non-nursing background but wish to enter the nursing field, direct entry msn programs online offer a fast-track option, letting you earn a master's degree in nursing and transition into advanced practice roles.

Some prospective nurses prioritize accessibility and flexible admission standards. If that's your focus, check out the easiest rn program to get into, which can help you start your nursing journey sooner.

For those interested in the administrative side of healthcare, taking medical coding and billing classes online with financial aid is a practical option that can lead to steady careers in healthcare management without patient care responsibilities.

Best Scientists Citing Céleste Lebbé

Trending Scientists